Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 9, 2002, Pages 4117-4121

  Cagnacci, Angelo ^a,b,c   Paoletti, Anna Maria ^a,b,c   Zanni, Annalisa ^a,b,c   Arangino, Serenella ^a,b,c   Ibba, Giulietta ^a,b,c   Orrù, Marisa ^a,b,c   Melis, Gian Benedetto ^a,b,c   Volpe, Annibale ^a,b,c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RALOXIFENE; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID METABOLISM; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OSTEOPENIA; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; BONE DISEASES, METABOLIC; C-PEPTIDE; ESTRADIOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLICLE STIMULATING HORMONE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; ITALY; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0036738453     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020120     Document Type: Article

References (34)

1. Cosman F, Lindsay R 1999 Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 20:418-434
2. Clemett D, Spencer CM 2000 Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60:379-411
3. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral desnity, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647
4. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637-645
5. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjamason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 281:2189-2197
6. Gorodeski GI, Utian WH 1994 Epidemiology and risk factors of cardiovascular disease in postmenopausal women. In: Lobo RA, ed. Treatment of the postmenopausal woman: basic and clinical aspects. New York: Raven Press Ltd.; 199-215
7. Rich-Edwards J, Manson JE, Hennekens CH, Buring JE 1995 The primary prevention of coronary heart disease in women. N Engl J Med 332:1758-1766
8. Kaseta JR, Skafar DF, Ram JL, Jacober SJ, Sowers JR 1999 Cardiovascular disease in the diabetic woman. J Clin Endocrinol Metab 84:1835-1838
9. Després J-P, Lamarche B, Mauriége P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ 1996 Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957
10. De Fronzo RA, Ferrannini E 1991 Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194
11. Reaven GM, Lithell H, Landsberg L 1996 Hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:375-381
12. Andres R 1971 Aging and diabetes. Med Clin N Am 55:835-846
13. Goldman JA, Reichman J, Resnik R 1980 Age-related glucose metabolism alterations in nondiabetic and potentially diabetic women. Maturitas 2:119-124
14. Gumbiner B, Polonsky KS, Beltz WF, Wallace P, Brechtel G, Fink RI 1989 Effects of aging on insulin secretion. Diabetes 38:1549-1556
15. Tonino RP, Minaker KL, Rowe JW 1989 Effect of age on systemic delivery or oral glucose in men. Diabetes Care 12:394-398
16. Elkind-Hirsch KE, Sherman LD, Malinak R 1993 Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab 76:472-475
17. Godsland IF, Gangar K, Walton C, Cust MP, Whitehead MI, Wynn V, Stevenson JC 1993 Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42:846-853
18. O'Sullivan AJ, Ho KKY 1995 A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 80:1783-1788
19. Kimmerle R, Heienemann L, Heise T, Bender R, Weyer C, Hirschberger S, Berger M 1999 Influence of continuous combined estradiol norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 6:36-42
20. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB 1992 Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 74:1396-1400
21. Cucinelli F, Paparella P, Soranna L, Barini A, Cinque B, Mancuso S, Lanzone A 1999 Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 140:215-223
22. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA 1993 A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60:664-667
23. Cagnacci A, Tuveri F, Cirillo R, Setteneri AM, Melis GB, Volpe A 1997 The effect of transdermal 17β-estradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration. Maturitas 28:163-167
24. Wilcox JG, Hwang J, Hodis HN, Sevanian A, Stanczyk FZ, Lobo RA 1997 Cardioprotective effects of individual conjugated estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 67:57-62
25. Raudaskoski T, Tomas C, Laatikainen T 1999 Insulin sensitivity during post-menopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel. Acta Obstet Gynecol Scand 78:540-545
26. Oleksik AM, Duoung T, Pliester N, Asma G, Popp-Snijders C, Lips P 2001 Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab 86:2763-2768
27. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW 1998 Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451
28. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW 2000 The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 85:214-218
29. Welch S, Gebhart SSP, Bergman RN, Phillips LS 1990 Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetics subjects. J Clin Endocrinol Metab 71:1508-1518
30. Friedewald WT, Levy RI, Fredrikson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preoperative ultracentrifuge. Clin Chem 18:499-502
31. American Diabetes Association Consensus Development Conference on Insulin Resistance 1998 Diabetes Care 21:310-314
32. Cagnacci A, Arangino S, Renzi A, Cagnacci P, Volpe A 2001 Insulin sensitivity in women: a comparison among values derived from intravenous glucose tolerance tests with different sampling frequency, oral glucose tolerance test or fasting. Eur J Endocrinol 145:281-287
33. Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB 1997 Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 82:251-253
34. Andersson B, Johannsson G, Holm G, Bengtsson BA, Sashegyi A, Pavo I, Mason T, Anderson PW 2002 Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type-2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab 87:122-128